Author name: admin

The EuCARE anual meeting was held in Lisbon at the Institute of Hygiene and Tropical Medicine on 15th and 16th of September 2022. In this meeting, the overall progress of the project was presented and discussed by all participants.

EuCARE has set up a collaboration with the Italian National Institute for the Evaluation of the Education and Training System, INVALSI

To read more go to publications or access through the link https://doi.org/10.3390/vaccines10040550

A paper on the The Impact of Sport Activity Shut down during the COVID-19 Pandemic on Children, Adolescents, and Young Adults.
To read more go to publications or access through the link https://www.mdpi.com/1660-4601/19/13/7908#cite

SARS-CoV-2 variants may escape monoclonal antibodies (mAbs) and antiviral drugs. This paper investigates differences in activity of mABs and antiviral drugs against newly emerging SARS-CoV-2 variants. To read more go to publications or access through the link https://www.mdpi.com/1999-4915/14/7/1374

This is a review paper where it is highlighted the main determinants of the emergence, epidemic response and available countermeasures of these three pandemics, and argued that such knowledge is paramount to prepare for the next pandemic. To read more about it go to publications or access through the link https://www.frontiersin.org/articles/10.3389/fmicb.2022.889643/full

In Italy, the pilot phase of the schools study of the European project “EuCARE: European cohorts of patients and schools to advance response to epidemics,” has started. To learn more see the interview Francesca Incardona gave to RA channel. Go to https://www.youtube.com/watch?v=sWKUdP_OOeU&t=6s.

To read more about it go to publications or access through the link https://www.mdpi.com/1660-4601/19/9/5384

The EuCARE session in the AREVIR meeting was held in Köln on 6 May 2022. In this session, the preliminary results of some of the WorkPackages of the project were presented.

Maruzio Zazzi presented recent results on the “Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies”